Weill Cornell
New York, NY
Filters
Save & Share
Clear Filters
Diagnosis
Treatment History
BCMA Therapy
This stands for B Cell Maturation Antigen (BCMA) and includes treatments such as ide-cel, cilta-cel or belantamab mafodotin.
Accepting patients
DREAMM12
A Study of Belantamab Mafodotin (GSK2857916) in Multiple Myeloma Participants With Normal and Varying Degrees of Impaired Renal Function
Learn more- Antibody Drug Conjugate (ADC)
- BCMA
- Phase 1
Accepting patients
Linvoseltamab
A Study to Examine the Effects of Novel Therapy Linvoseltamab in Combination With Other Cancer Treatments for Adult Patients With Multiple Myeloma That is Resistant to Current Standard of Care Treatments
Learn more- Bispecific Antibody
- BCMA
- Phase 1
Accepting patients
APG-2575
APG-2575 in Combination With Novel Therapeutic Regimens in Subjects With Relapsed or Refractory Multiple Myeloma
Learn more- BCL-2 Inhibitor
- Phase 1/2
- Has results
Accepting patients
Investigational Cord Blood Units
Safety Study of Unlicensed, Investigational Cord Blood Units Manufactured by the National Cord Blood Program (NCBP) for Unrelated Transplantation
Learn more- Allogeneic Stem Cell Transplant
- Cord Blood
- Phase 2
Accepting patients
ISB 1442
Phase 1/2 Study of ISB 1442 in Relapsed/Refractory Multiple Myeloma
Learn more- Bispecific Antibody
- CD38
- CD47
- Phase 1/2
- Has results
Accepting patients
IDP-023
Phase 1/2 Study of IDP-023 as a Single Agent and in Combination With Antibody Therapies in Patients With Advanced Hematologic Cancers
Learn more- Natural Killer Cells (Allogeneic)
- Phase 1/2
Accepting patients
D-ClaPd
A Phase II Study of Daratumumab, Clarithromycin, Pomalidomide And Dexamethasone (D-ClaPd) In Multiple Myeloma Patients Previously Exposed to Daratumumab
Learn more- Monoclonal Antibody
- CD38
- Phase 2